文献速递前列腺癌

少数族裔服务医院在中危和高危局限性前列腺癌治疗中的医疗质量

Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.
PubMed 文献 · J Urol · 2019-01-01

基于美国国家癌症数据库2004至2015年536,539例40岁以上局限性中危和高危前列腺癌男性患者,研究将收治黑人和西班牙裔患者比例最高的十分之一机构定义为少数族裔服务医院。多变量分析显示,在少数族裔服务医院治疗与接受根治性治疗的几率降低(aOR 0.73,95%CI 0.62-0.85,p<0.001)及治疗时间延长(调整后均值差4.9±2.2天,p=0.024)相关;在年轻且健康接受外照射放疗的男性中,与同期接受雄激素剥夺治疗无关(AOR 0.90,95%CI 0.75-1.09,p=0.291)。

要点

  • 少数族裔服务医院治疗与接受根治性治疗几率降低相关(aOR 0.73)。
  • 少数族裔服务医院的治疗时间显著更长(调整后均值差4.9天)。
  • 年轻健康男性外照射放疗时是否联用ADT与医院类型无关。

核心结论

  • 在调整种族因素后,少数族裔服务医院治疗仍与局限性中危和高危前列腺癌患者接受根治性治疗几率降低及治疗时间延长相关。
  • 研究提示部分前列腺癌的种族差异可能由少数族裔患者接受治疗的机构场所解释。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性队列研究,纳入2004至2015年536,539例40岁及以上局限性中危和高危前列腺癌男性患者。
  • 按机构收治黑人和西班牙裔患者比例排名,前十分之一机构定义为少数族裔服务医院(162家),其余为非少数族裔服务医院(1,168家)。
  • 采用多变量分析评估医院类型与三个终点指标的关联:接受根治性治疗、至根治性治疗时间、以及年轻(≤65岁)且健康(无合并症)接受外照射放疗男性中联用雄激素剥夺治疗。

主要发现

  • 少数族裔服务医院治疗与接受根治性治疗的几率降低相关(调整OR 0.73,95%CI 0.62-0.85,p<0.001)。
  • 少数族裔服务医院的调整后平均至治疗时间显著长于非少数族裔服务医院(调整后均值±SE差4.9±2.2天,p=0.024)。
  • 在年轻且健康接受外照射放疗的男性中,少数族裔服务医院治疗与联用雄激素剥夺治疗无显著关联(AOR 0.90,95%CI 0.75-1.09,p=0.291)。

临床怎么用

  • 临床转诊或制定治疗计划时,应关注少数族裔服务医院可能存在的根治性治疗可及性延迟和几率降低问题。
  • 针对局限性中危和高危前列腺癌患者,尤其在少数族裔服务医院就诊者,需优化治疗路径以减少延迟并确保根治性治疗的实施。

局限性

  • 研究为基于国家癌症数据库的回顾性分析,可能存在未测量混杂因素。
  • 少数族裔服务医院的定义基于收治黑人和西班牙裔患者比例的前十分之一,可能受机构规模或地区影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the quality of care at minority serving hospitals compared to other institutions for men with localized intermediate and high risk prostate cancer. MATERIALS AND METHODS: Using the National Cancer Database we identified 536,539 men 40 years old or older who presented with localized intermediate and high risk prostate cancer in the United States between 2004 and 2015. Institutions were ranked according to the proportion of black and Hispanic patients treated at a given institution, and the top decile institutions were defined as minority serving hospitals. We used multivariable analyses to characterize the association between minority serving hospitals and 3 end points, including receipt of definitive treatment, time to definitive treatment and receipt of androgen deprivation therapy in young (65 years or younger) and healthy (no comorbidity) men treated with external beam radiation therapy. RESULTS: A total of 162 and 1,168 hospitals were defined as minority and nonminority serving hospitals, respectively. On multivariable analyses treatment at minority serving hospitals was associated with decreased odds of receiving definitive treatment (adjusted OR 0.73, 95% CI 0.62-0.85, p <0.001). Adjusted mean ± SE time to treatment was significantly longer at minority serving hospitals compared to nonminority serving hospitals (4.9 ± 2.2 days, p = 0.024). Among young and healthy men there was no association between treatment at a minority serving hospital and receipt of androgen deprivation therapy in conjunction with external beam radiation (AOR 0.90, 95% CI 0.75-1.09, p = 0.291). CONCLUSIONS: Treatment at a minority serving hospital was associated with lower odds of receiving definitive therapy and longer time to definitive therapy for localized intermediate and high risk prostate cancer despite adjustment for race. This suggests that some racial disparities in prostate cancer may be explained by the sites at which racial and/or ethnic minorities receive care.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Krimphove MJ, Fletcher SA, Cole AP, et al. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019. PMID: 30414956. doi:10.1016/j.juro.2018.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。